146 related articles for article (PubMed ID: 9402559)
1. Elvax as a slow-release delivery agent for a platelet-activating factor receptor agonist and antagonist.
Bix GJ; Clark GD
J Neurosci Methods; 1997 Nov; 77(1):67-74. PubMed ID: 9402559
[TBL] [Abstract][Full Text] [Related]
2. Changes in cytosolic free calcium induced by platelet-activating factor in rabbit platelets: specific inhibition by BN 52021 and structurally related compounds.
Baroggi N; Etienne A; Braquet P
Agents Actions Suppl; 1986; 20():87-97. PubMed ID: 3028108
[TBL] [Abstract][Full Text] [Related]
3. Triflavin potentiates the antiplatelet activity of platelet activating factor receptor antagonist on activated neutrophil-induced platelet aggregation.
Lee LW; Peng HC; Ko WC; Hung WC; Su CH; Lin CH; Huang TF; Yen MH; Sheu JR
Eur J Pharmacol; 1999 Jan; 364(2-3):239-46. PubMed ID: 9932729
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of the metabolism of platelet activating factor (PAF-acether) by three specific antagonists from Ginkgo biloba.
Lamant V; Mauco G; Braquet P; Chap H; Douste-Blazy L
Biochem Pharmacol; 1987 Sep; 36(17):2749-52. PubMed ID: 2820421
[TBL] [Abstract][Full Text] [Related]
5. Comparison of three paf-acether receptor antagonist ginkgolides.
Korth R; Nunez D; Bidault J; Benveniste J
Eur J Pharmacol; 1988 Jul; 152(1-2):101-10. PubMed ID: 2850196
[TBL] [Abstract][Full Text] [Related]
6. Characterization of receptors for platelet-activating factor on platelets, polymorphonuclear leukocytes and macrophages.
Stewart AG; Dusting GJ
Br J Pharmacol; 1988 Aug; 94(4):1225-33. PubMed ID: 2850058
[TBL] [Abstract][Full Text] [Related]
7. Role of platelet-activating factor in long-term potentiation of the rat medial vestibular nuclei.
Grassi S; Francescangeli E; Goracci G; Pettorossi VE
J Neurophysiol; 1998 Jun; 79(6):3266-71. PubMed ID: 9636125
[TBL] [Abstract][Full Text] [Related]
8. The accumulation of platelet activating factor in the injured cornea may be interrelated with the synthesis of lipoxygenase products.
Bazan HE; Reddy ST; Woodland JM; Bazan NG
Biochem Biophys Res Commun; 1987 Dec; 149(3):915-20. PubMed ID: 2827658
[TBL] [Abstract][Full Text] [Related]
9. [The effect of platelet-activating factor and its antagonist--BN 52021--on immune reactions in vivo in mice and in vitro].
Poveshchenko AF; Kozlov VA
Zh Mikrobiol Epidemiol Immunobiol; 1999; (4):53-6. PubMed ID: 10852052
[TBL] [Abstract][Full Text] [Related]
10. Antagonism of vasoconstriction induced by platelet-activating factor in guinea-pig perfused hearts by selective platelet-activating factor receptor antagonists.
Piper PJ; Stewart AG
Br J Pharmacol; 1987 Apr; 90(4):771-83. PubMed ID: 3034369
[TBL] [Abstract][Full Text] [Related]
11. PAF binding sites. Characterization by [3H]52770 RP, a pyrrolo[1,2-c]thiazole derivative, in rabbit platelets.
Robaut C; Durand G; James C; Lave D; Sedivy P; Floch A; Mondot S; Pacot D; Cavero I; Le Fur G
Biochem Pharmacol; 1987 Oct; 36(19):3221-9. PubMed ID: 2822048
[TBL] [Abstract][Full Text] [Related]
12. Reversible or irreversible modification of [3H]PAF binding on rabbit platelet membranes differentiates various PAF receptor antagonists.
Domingo MT; Piro F; Broquet C; Auclair E; Chabrier PE; Braquet P
Lipids; 1992 Aug; 27(8):582-6. PubMed ID: 1328798
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of transmembrane movement and metabolism of platelet activating factor (PAF-acether) by a specific antagonist, BN 52021.
Lachachi H; Plantavid M; Simon MF; Chap H; Braquet P; Douste-Blazy L
Biochem Biophys Res Commun; 1985 Oct; 132(2):460-6. PubMed ID: 2998370
[TBL] [Abstract][Full Text] [Related]
14. Inhibition by BN 52021 (ginkgolide B) of the binding of [3H]-platelet-activating factor to human neutrophil granulocytes.
Földes-Filep E; Braquet P; Filep J
Biochem Biophys Res Commun; 1987 Nov; 148(3):1412-7. PubMed ID: 2825685
[TBL] [Abstract][Full Text] [Related]
15. Prehispanolone, a novel platelet activating factor receptor antagonist from Leonurus heterophyllus.
Lee CM; Jiang LM; Shang HS; Hon PM; He Y; Wong HN
Br J Pharmacol; 1991 Jul; 103(3):1719-24. PubMed ID: 1657264
[TBL] [Abstract][Full Text] [Related]
16. Effect of a platelet-activating factor (PAF) receptor antagonist on hyperacute xenograft rejection; evaluation in a pig kidney-human blood xenoperfusion model.
Cruzado JM; Torras J; Riera M; Lloberas N; Herrero I; Condom E; Martorell J; Alsina J; Grinyó JM
Clin Exp Immunol; 1998 Jul; 113(1):136-44. PubMed ID: 9697996
[TBL] [Abstract][Full Text] [Related]
17. Motility induced by human immunodeficiency virus-1 Tat on Kaposi's sarcoma cells requires platelet-activating factor synthesis.
Biancone L; Cantaluppi V; Boccellino M; Bussolati B; Del Sorbo L; Conaldi PG; Albini A; Toniolo A; Camussi G
Am J Pathol; 1999 Nov; 155(5):1731-9. PubMed ID: 10550329
[TBL] [Abstract][Full Text] [Related]
18. Platelet-activating factor (PAF) receptor antagonists inhibit arachidonic acid induced platelet aggregation in rabbit whole blood.
Ammit AJ; O'Neill C
Lipids; 1991 Dec; 26(12):1189-92. PubMed ID: 1668116
[TBL] [Abstract][Full Text] [Related]
19. Platelet-activating factor induces cell death in cultured astrocytes and oligodendrocytes: involvement of caspase-3.
Hostettler ME; Knapp PE; Carlson SL
Glia; 2002 May; 38(3):228-39. PubMed ID: 11968060
[TBL] [Abstract][Full Text] [Related]
20. Proof of the involvement of platelet activating factor (paf-acether) in pulmonary complex immune systems using a specific paf-acether receptor antagonist: BN 52021.
Touvay C; Vilain B; Taylor JE; Etienne A; Braquet P
Prog Lipid Res; 1986; 25(1-4):277-88. PubMed ID: 2827186
[No Abstract] [Full Text] [Related]
[Next] [New Search]
